← Eichor
Condition: Grade 3A Follicular Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Grade 3A Follicular Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
Phase 2 · 1 location(s) · Evopoint Biosciences Inc. · NCT07545603Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06471738Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Phase 1/Phase 2 · 5 location(s) · Pell Bio-Med Technology Co., Ltd. · NCT05326243Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Tri
Phase 2 · 1 location(s) · University of Washington · NCT06948786Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Ly
Phase 2 · 2 location(s) · City of Hope Medical Center · NCT06453044Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody
Phase 3 · 12 location(s) · Heidelberg University · NCT05045664Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Rel
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06859008Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Phase N/A · 5 location(s) · Pell Bio-Med Technology Co., Ltd. · NCT05377307Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgk
Phase 2 · 1 location(s) · Emory University · NCT04883437Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Phase 2 · 1 location(s) · University of Washington · NCT06442475
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.